Stock BRNS BARINTHUS BIOTHERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
2.55 USD -2.67% Intraday chart for Barinthus Biotherapeutics plc -1.92% -30.89%
Apr. 18 Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours MT
Apr. 18 BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections CI

Business Summary

Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

Number of employees: 130

Sales per Business

USD in Million2022Weight2023Weight Delta
Immunotherapies and Vaccines
100.0 %
45 100.0 % 1 100.0 % -98.21%

Sales per region

USD in Million2022Weight2023Weight Delta
United Kingdom and United States
100.0 %
45 100.0 % 1 100.0 % -98.21%

Managers

Managers TitleAgeSince
William Enright CEO
 Chief Executive Officer 61 19-07-31
Gemma Brown DFI
 Director of Finance/CFO 34 21-08-31
Nadège Pelletier CTO
 Chief Tech/Sci/R&D Officer 46 23-01-31
Jonothan Blackbourn IRC
 Investor Relations Contact - 22-09-30
Graham Griffiths PRN
 Corporate Officer/Principal 45 17-09-30

Members of the board

Members of the board TitleAgeSince
Karen Dawes BRD
 Director/Board Member 72 21-02-28
William Enright CEO
 Chief Executive Officer 61 19-07-31
Anne Phillips BRD
 Director/Board Member 70 21-02-20
Robin Wright CHM
 Chairman 59 18-09-30
Pierre Armand Morgon BRD
 Director/Board Member 61 17-12-31
Alex Hammacher BRD
 Director/Board Member 43 19-12-31
Joseph Scheeren BRD
 Director/Board Member 68 21-03-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,643,540 37,217,593 ( 96.31 %) 0 47.98 %
Stock B 1 38,921,212 0 0

Shareholders

NameEquities%Valuation
M&G Investment Management Ltd.
13.48 %
5,197,349 13.48 % 12 M $
ALPHABET INC.
3.927 %
1,513,644 3.927 % 4 M $
Hongshan
3.685 %
1,420,473 3.685 % 3 M $
DC Funds LP
1.666 %
642,204 1.666 % 2 M $
BlueCrest Capital Management (UK) LLP
1.408 %
542,673 1.408 % 1 M $
Robert W. Baird & Co., Inc. (Equity)
0.5092 %
196,296 0.5092 % 467 184 $
The Johns Hopkins University
0.2801 %
107,968 0.2801 % 256 964 $
Renaissance Technologies LLC
0.0770 %
29,699 0.0770 % 70 684 $
Ipswich Investment Management Co., Inc.
0.0599 %
23,075 0.0599 % 54 919 $
Morgan Stanley Smith Barney LLC
0.0427 %
16,467 0.0427 % 39 191 $
NameEquities%Valuation
Oxford Science Enterprises PLC
25.83 %
8,797,770 25.83 % 21 M $
William Enright
3.650 %
1,243,377 3.650 % 3 M $
Graham Griffiths
0.3059 %
104,209 0.3059 % 248 017 $
Robin Wright
0.1417 %
48,256 0.1417 % 114 849 $
Joseph Scheeren
0.0675 %
23,000 0.0675 % 54 740 $
Pierre Armand Morgon
0.0308 %
10,506 0.0308 % 25 004 $
Anne Phillips
0.008807 %
3,000 0.008807 % 7 140 $
Alex Hammacher
0.008807 %
3,000 0.008807 % 7 140 $
Karen Dawes
0.004991 %
1,700 0.004991 % 4 046 $
Chris Ellis
0.000220 %
75 0.000220 % 179 $

Company contact information

Vaccitech Plc

Zeus Building Rutherford Avenue

OX11 0DF, Didcot

+

http://www.vaccitech.co.uk
address Barinthus Biotherapeutics plc(BRNS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.62 USD
Average target price
7.4 USD
Spread / Average Target
+182.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BARINTHUS BIOTHERAPEUTICS PLC Stock Barinthus Biotherapeutics plc
-30.89% 102M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 40.08B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 40B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 26.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 24.58B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 11.66B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.01B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BRNS Stock
  4. Company Barinthus Biotherapeutics plc